ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pralatrexate

Also written as “Pralatrexate Injection”, “Pralatrexate” and “Folotyn”.

Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Lymphoma, T-Cell, Cutaneous · Hematologic Neoplasms · Lymphoma, B-Cell, led by 3 companies.

Drug pagePralatrexate: every studyAll 34 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 19, 202319 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aurobindo Pharma122 open or runningphase 3since Sep 19, 2023Aug 14, 2006Feb 2027phase 1 · NCT07036133
Zydus Lifesciencesits history only40 open or runningphase 3since Aug 18, 2011Jan 24, 2003none ahead
Mundipharmaits history only30 open or runningphase 4since May 5, 2017Dec 4, 2013none ahead

Also a collaborator on its studies: Axis Clinicals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aurobindo Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 14, 2006First study: phase 2 study in Lymphoma, T-Cell, PeripheralFirst studyNCT00364923 · 115 enrolled · United States, Belgium, Canada and more
  2. Jun 1, 2007Phase 2 study in RecurrenceNCT00481871 · 119 enrolled · United States
  3. Nov 5, 2007Phase 1 study in Lymphoma, T-Cell, CutaneousNCT00554827 · 55 enrolled · United States
  4. Jul 23, 2008Phase 2 study in Carcinoma, Transitional CellNCT00722553 · 30 enrolled · United States, Argentina, Belgium and more
  5. May 5, 2010Phase 2 study in Breast NeoplasmsNCT01118624 · 22 enrolled · United States, Czechia, France and more
  6. May 28, 2010Phase 1 study in Lymphoma, T-Cell, CutaneousNCT01134341 · 34 enrolled · United States, Italy
  7. Feb 7, 2013Phase 1 study in Lymphoma, Non-HodgkinNCT01789723
  8. Mar 21, 2013Phase 1 study in Carcinoma, Non-Small-Cell LungNCT01820091
  9. Mar 28, 2014Phase 2 study in Lymphoma, T-Cell, PeripheralNCT02106650 · 36 enrolled · United States
  10. Sep 25, 2015Phase 1 study in Lymphoma, T-Cell, PeripheralNCT02594267 · 48 enrolled · United States
  11. Sep 19, 2023Phase 3 study in Lymphoma, T-Cell, PeripheralNCT06072131 · 504 enrolled · United States, Canada, Germany and more
  12. Mar 18, 2025Phase 1 study in Hematologic NeoplasmsNCT07036133 · 24 planned · United States

Ahead

  1. Feb 2027Primary completion: phase 1 study in Hematologic NeoplasmsNCT07036133
  2. Jul 2030Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralNCT06072131

TargetBeta

DHFR →RFC1 →read by rule
“A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities”NCIt, by rule
“Dihydrofolate reductase inhibitor”ChEMBL 37, by rule

Studies

All 12 Aurobindo Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07036133Hematologic Neoplasms · United States1RecruitingFeb 202724
NCT06072131Lymphoma, T-Cell, Peripheral · United States, Canada, Germany and more3Active, not recruitingJul 2030504
NCT02594267Lymphoma, T-Cell, Peripheral · United States1CompletedApr 7, 201748
NCT02106650Lymphoma, T-Cell, Peripheral · United States2CompletedOct 201836
NCT01820091Carcinoma, Non-Small-Cell Lung1WithdrawnApr 20150
NCT01789723Lymphoma, Non-Hodgkin1WithdrawnMar 20150
NCT01134341Lymphoma, T-Cell, Cutaneous · United States, Italy1CompletedAug 201534
NCT01118624Breast Neoplasms · United States, Czechia, France and more2CompletedApr 201222
NCT00722553Carcinoma, Transitional Cell · United States, Argentina, Belgium and more2CompletedApr 201130
NCT00554827Lymphoma, T-Cell, Cutaneous · United States1CompletedJan 201255
NCT00481871Recurrence · United States2CompletedMay 2011119
NCT00364923Lymphoma, T-Cell, Peripheral · United States, Belgium, Canada and more2CompletedJan 2009115

How it is read

Names in the registry

  • “Pralatrexate Injection”, 9 entries
  • “Pralatrexate”, 4 entries
  • “pralatrexate”, 2 entries
  • “Folotyn”, 2 entries
  • “Folotyn and Leucovorin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.